My ePortfolio Register   

RANGE: docetaxel with or without ramucirumab for metastatic urothelial carcinoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 457

Prof Daniel Petrylak - Yale Cancer Center, New Haven, Connecticut, USA

Prof Petrylak presents in a press conference at the ESMO 2017 Congress data from the RANGE trial looking at the use of docetaxel with or without ramucirumab in previously treated patients with locally advanced, unresectable, or metastatic urothelial carcinoma. 

For more information read our news coverage or watch the interview

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence